Human leukocyte antigen G receptor axis (HLA-G receptor axis)

The **Human leukocyte antigen G receptor axis** refers to the set of interactions between **HLA-G**, a non-classical major histocompatibility complex class I molecule, and specific inhibitory receptors expressed primarily on natural killer (NK) cells and some T lymphocytes—namely **leukocyte immunoglobulin-like receptor subfamily B member 1** (**LILRB1**), **leukocyte immunoglobulin-like receptor subfamily B member 2** (**LILRB2**), and **killer cell immunoglobulin-like receptor 2DL4** (**KIR2DL4**) [1][3][4]. These interactions play critical roles in modulating innate immunity by delivering inhibitory signals that suppress cytotoxicity, promote apoptosis/exhaustion in chronic infection settings such as tuberculosis [3], facilitate maternal-fetal tolerance during pregnancy [1], and contribute to tumor immune evasion when aberrantly expressed by cancer cells [3]. The molecular basis involves high-affinity binding between unique residues within the α domains of HLA-G and their respective contact sites within these receptors [2]. Therapeutically targeting this pathway is under investigation for reversing pathological states associated with excessive immune suppression—such as cancer—or restoring normal immunity during chronic infections. However, because these pathways are essential for physiological processes like pregnancy maintenance, therapeutic intervention carries significant risks related to breaking self-tolerance. References used above provide detailed mechanistic insights into each component's structure-function relationship within this regulatory network[1][2][3][4].

Other names

HLA-G interaction with LILRB1HLA-G interaction with LILRB2HLA-G interaction with KIR2DL4Leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1)Leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2)Killer cell immunoglobulin-like receptor 2DL4 (KIR2DL4)Non-classical MHC class I molecule interactions

Drugs or antibodies targeting this pathway would act by blocking the binding between HLA-G and its receptors on immune cells, thereby restoring cytotoxic activity or reversing immunosuppression/exhaustion. For example, anti-HLA-G monoclonal antibodies can neutralize the suppressive effect on NK cells mediated through LILRB1.